NPCE
Neuropace Inc
14.50$
+1.8%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +9.6% | +0.6% | +6.2% | +9.4% | +1.9% | +4.9% | +4.4% | +16.3% | -2.8% | -17.0% | +3.4% | – | |
| – | +6.5% | +7.0% | +7.1% | +10.1% | -6.4% | -1.8% | +4.0% | +14.8% | -2.8% | -33.1% | -2.5% | – | |
| – | +10.7% | -1.5% | +5.9% | +9.1% | +5.0% | +7.1% | +4.6% | +16.7% | -2.8% | -12.3% | +4.8% | – | |
| – | +12.1% | +7.6% | +4.9% | -5.1% | +5.1% | +23.0% | -8.0% | -3.9% | +6.9% | +2.3% | -4.0% | – | |
| – | -1.3% | +14.3% | -69.9% | +206.2% | -0.8% | -70.7% | +50.0% | -24.3% | -4.6% | +10.5% | +3.8% | – | |
| – | +2.3% | +12.3% | -2.5% | -3.4% | +0.9% | +13.3% | +11.0% | -4.8% | -6.0% | +5.7% | +1.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +2.1% | +1.0% | -4.1% | +0.7% | +0.5% | -1.8% | -4.4% | -20.1% | -2.7% | -4.9% | +1.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -471.8% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.